Correlation Between PsyBio Therapeutics and Algernon Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both PsyBio Therapeutics and Algernon Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining PsyBio Therapeutics and Algernon Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between PsyBio Therapeutics Corp and Algernon Pharmaceuticals, you can compare the effects of market volatilities on PsyBio Therapeutics and Algernon Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in PsyBio Therapeutics with a short position of Algernon Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of PsyBio Therapeutics and Algernon Pharmaceuticals.

Diversification Opportunities for PsyBio Therapeutics and Algernon Pharmaceuticals

-0.12

Correlation Coefficient

PsyBio Therapeutics  Algernon Pharmaceuticals

Good diversification

The 3 months correlation between PsyBio and Algernon is -0.12. Overlapping area represents the amount of risk that can be diversified away by holding PsyBio Therapeutics Corp and Algernon Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Algernon Pharmaceuticals and PsyBio Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on PsyBio Therapeutics Corp are associated (or correlated) with Algernon Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Algernon Pharmaceuticals has no effect on the direction of PsyBio Therapeutics i.e., PsyBio Therapeutics and Algernon Pharmaceuticals go up and down completely randomly.

Pair Corralation between PsyBio Therapeutics and Algernon Pharmaceuticals

Assuming the 90 days horizon PsyBio Therapeutics Corp is expected to generate 13.37 times more return on investment than Algernon Pharmaceuticals. However, PsyBio Therapeutics is 13.37 times more volatile than Algernon Pharmaceuticals. It trades about 0.11 of its potential returns per unit of risk. Algernon Pharmaceuticals is currently generating about -0.01 per unit of risk. If you would invest  0.85  in PsyBio Therapeutics Corp on September 4, 2024 and sell it today you would lose (0.35) from holding PsyBio Therapeutics Corp or give up 41.18% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.43%
Values	Daily Returns

PsyBio Therapeutics Corp  vs.  Algernon Pharmaceuticals

PsyBio Therapeutics Corp

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in PsyBio Therapeutics Corp are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental drivers, PsyBio Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Algernon Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Algernon Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest inconsistent performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.

Pair Trading with PsyBio Therapeutics and Algernon Pharmaceuticals

The main advantage of trading using opposite PsyBio Therapeutics and Algernon Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if PsyBio Therapeutics position performs unexpectedly, Algernon Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Algernon Pharmaceuticals will offset losses from the drop in Algernon Pharmaceuticals' long position.

The idea behind PsyBio Therapeutics Corp and Algernon Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.